Evidence map›Paper›PMID 36702126›Full record

ArticleMolecular cell2023

SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses.

Shouhai Zhu, Jing Hou, Huanyao Gao, Qi Hu, Jake A Kloeber, Jinzhou Huang, Fei Zhao, Qin Zhou, Kuntian Luo, Zheming Wu and 3 more

Open access · greenAbstract read
In one paragraph

Article in Molecular cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. HIV-1 Vif-dependent SUMOylation regulates viral RNA splicing.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Shouhai ZhuDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Jing HouDepartment of Breast Surgery, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550002, China.
Huanyao GaoDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Qi HuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
Jake A KloeberDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA; Mayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, MN 55905, USA.
Jinzhou HuangDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Fei ZhaoDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Qin ZhouDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Kuntian LuoDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Zheming WuDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Xinyi TuDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Ping YinDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: lou.zhenkun@mayo.edu.
Mayo Clinic in Arizona · USGuizhou Provincial People's Hospital · CNMayo Clinic · USWinnMed · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Regulation of homologous recombination and cancer cell response to chemoradiotherapyR01CA203561 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2016 to 2020
$1.8M
UFM1 signaling in DNA damage response and cancer therapyR01CA217183 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2018 to 2022
$1.8M
Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatmentR01CA264600 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2021 to 2025
$1.8M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA203561NCI NIH HHS R01 CA217183NCI NIH HHS R01 CA264600NIGMS NIH HHS T32 GM065841
6 · The paper itself

Abstract

Replication protein A (RPA) is a major regulator of eukaryotic DNA metabolism involved in multiple essential cellular processes. Maintaining appropriate RPA dynamics is crucial for cells to prevent RPA exhaustion, which can lead to replication fork breakage and replication catastrophe. However, how cells regulate RPA availability during unperturbed replication and in response to stress has not been well elucidated. Here, we show that HNRNPA2B1

Indexed as

DNA ReplicationReplication Protein AAtaxia Telangiectasia Mutated ProteinsChromatinDNA DamageSumoylationAtaxia Telangiectasia Mutated ProteinsChromatinReplication Protein AATRATRIPbreast cancerDNA damageHNRNPA2B1homologous recombinationreplication stressRPASUMOylation

Identifiers

PMID36702126
PMCPMC9975078
OpenAlexW4317940449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.